Physician profile
Tracy Van Meter
NPI 1386775849
$337.29
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $215 · 2021: $15.13.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $89.42 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.92 | 2019-2020 | |
| Lilly USA, LLC | $36.34 | 2020 | |
| Eisai INC. | $34.19 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $19.12 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.88 | 2020 | |
| Foundation Medicine, INC. | $17.84 | 2020 | |
| Genzyme Corporation | $15.66 | 2019 | |
| Celgene Corporation | $13.91 | 2019 | |
| Karyopharm Therapeutics INC. | $13.05 | 2020 | |
| Seagen INC. | $12.96 | 2020 | |
| Incyte Corporation | $12.00 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Van Meter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.